NZ742805B2 - Anti-cd22 antibody-maytansine conjugates and methods of use thereof - Google Patents

Anti-cd22 antibody-maytansine conjugates and methods of use thereof

Info

Publication number
NZ742805B2
NZ742805B2 NZ742805A NZ74280516A NZ742805B2 NZ 742805 B2 NZ742805 B2 NZ 742805B2 NZ 742805 A NZ742805 A NZ 742805A NZ 74280516 A NZ74280516 A NZ 74280516A NZ 742805 B2 NZ742805 B2 NZ 742805B2
Authority
NZ
New Zealand
Prior art keywords
amino acid
conjugate
sequence
fgly
present
Prior art date
Application number
NZ742805A
Other versions
NZ742805A (en
Inventor
Robyn M Barfield
Penelope M Drake
Jesse M Mcfarland
David Rabuka
Original Assignee
Rp Scherer Technologies Llc
Filing date
Publication date
Application filed by Rp Scherer Technologies Llc filed Critical Rp Scherer Technologies Llc
Priority claimed from PCT/US2016/060996 external-priority patent/WO2017083306A1/en
Publication of NZ742805A publication Critical patent/NZ742805A/en
Publication of NZ742805B2 publication Critical patent/NZ742805B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Claims (29)

WHAT IS CLAIMED IS:
1. A conjugate of formula (I): (I) wherein W2 is an anti-CD22 antibody that includes at least one modified amino acid residue.
2. The conjugate of Claim 1, wherein the anti-CD22 antibody binds an epitope within amino acids 1 to 846, within amino acids 1-759, within amino acids 1-751, or within amino acids 1-670, of a CD22 amino acid sequence depicted in FIG. 8A-8C.
3. The conjugate of Claim 1, wherein the anti-CD22 antibody comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid.
4. The conjugate of Claim 3, wherein the sequence is L(FGly’)TPSR. N O O OH O O N O OMe O NH O N O O O Cl OMe O N OH O N N N W2 142
5. The conjugate of Claim 3, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
6. The conjugate of Claim 1, wherein the modified amino acid residue is positioned at a Cterminus of a heavy chain constant region of the anti-CD22 antibody.
7. The conjugate of Claim 6, wherein the heavy chain constant region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence is C-terminal to the amino acid sequence SLSLSPG.
8. The conjugate of Claim 7, wherein the heavy chain constant region comprises the sequence SPGSL(FGly’)TPSRGS.
9. The conjugate of Claim 7, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
10. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a light chain constant region of the anti-CD22 antibody. 143
11. The conjugate of Claim 10, wherein the light chain constant region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence C-terminal to the sequence KVDNAL, and/or is N-terminal to the sequence QSGNSQ.
12. The conjugate of Claim 11, wherein the light chain constant region comprises the sequence KVDNAL(FGly’)TPSRQSGNSQ.
13. The conjugate of Claim 11, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
14. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a heavy chain CH1 region of the anti-CD22 antibody.
15. The conjugate of Claim 14, wherein the heavy chain CH1 region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; 144 Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence is C-terminal to the amino acid sequence SWNSGA and/or is Nterminal to the amino acid sequence GVHTFP.
16. The conjugate of Claim 15, wherein the heavy chain CH1 region comprises the sequence SWNSGAL(FGly’)TPSRGVHTFP.
17. The conjugate of Claim 15, wherein Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
18. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a heavy chain CH2 region of the anti-CD22 antibody.
19. The conjugate of Claim 1, wherein the modified amino acid residue is positioned in a heavy chain CH3 region of the anti-CD22 antibody.
20. A pharmaceutical composition comprising: a conjugate of any one of Claims 1 to 19; and a pharmaceutically acceptable excipient.
21. A use of the conjugate of any one of Claims 1 to 19 or the pharmaceutical composition of claim 20 in the manufacture of a medicament.
22. A use of the conjugate of any one of Claims 1 to 19 or the pharmaceutical composition of claim 20, in the manufacture of a medicament for treating cancer in a subject. 145
23. A use of the conjugate of any one of claims 1 to 19 or the pharmaceutical composition of claim 20, in the manufacture of a medicament for delivering a drug to a target site in a subject, wherein the medicament is to be administered to a subject, wherein the administering is effective to release a therapeutically effective amount of the drug from the conjugate at the target site in the subject.
24. The use of claim 22, wherein the cancer is a carcinoma, sarcoma, leukemia, or lymphoma.
25. The use of claim 24, wherein the lymphoma is B-cell lymphomas, Hodgkin’s lymphoma, or non-Hodgkin’s B cell lymphoma.
26. The conjugate of Claim 6, wherein the modified amino acid residue is positioned at a Cterminus of a heavy chain CH3 region of the anti-CD22 antibody,
27. The conjugate of Claim 26, wherein the heavy chain CH3 region comprises a sequence of the formula (II): X 1 (FGly’)X2Z 20X 3Z 30 (II) wherein FGly’ is the modified amino acid residue of formula (I); Z 20 is either a proline or alanine residue; Z 30 is a basic amino acid or an aliphatic amino acid; X 1 may be present or absent and, when present, can be any amino acid, with the proviso that when the sequence is at the N-terminus of the conjugate, X1 is present; and X 2 and X3 are each independently any amino acid, and wherein the sequence is C-terminal to the amino acid sequence SLSLSPG.
28. The conjugate of Claim 26, wherein the heavy chain CH3 region comprises the sequence SPGSL(FGly’)TPSRGS.
29. The conjugate of Claim 26, wherein 146 Z 30 is selected from R, K, H, A, G, L, V, I, and P; X 1 is selected from L, M, S, and V; and X 2 and X3 are each independently selected from S, T, A, V, G, and C.
NZ742805A 2016-11-08 Anti-cd22 antibody-maytansine conjugates and methods of use thereof NZ742805B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252985P 2015-11-09 2015-11-09
PCT/US2016/060996 WO2017083306A1 (en) 2015-11-09 2016-11-08 Anti-cd22 antibody-maytansine conjugates and methods of use thereof

Publications (2)

Publication Number Publication Date
NZ742805A NZ742805A (en) 2023-12-22
NZ742805B2 true NZ742805B2 (en) 2024-03-26

Family

ID=

Similar Documents

Publication Publication Date Title
EP4241847A3 (en) Improved cell-targeting binding molecule
WO2015095301A3 (en) Cytotoxic peptides and conjugates thereof
FI3389699T3 (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
MX2020002666A (en) Anti- folate receptor alpha antibody conjugates and their uses.
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
WO2020236817A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2021005134A (en) Cytostatic conjugates with integrin ligands.
MX2016016515A (en) Auristatin derivatives and conjugates thereof.
RU2016129894A (en) COVALENTLY RELATED HELICAR-ANTIBODY CONJUGATES AGAINST HELICAR AND THEIR APPLICATION
JP2017518304A5 (en)
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
RU2010145177A (en) LIVER CANCER TREATMENT
MX2020010300A (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof.
RU2016106339A (en) ANTI-NER2 ANTIBODY AND ITS CONJUGATE
WO2018204872A3 (en) Igf-1r monoclonal antibodies and uses thereof
CN106999540B (en) Combination therapy
WO2020123836A9 (en) Herboxidiene antibody-drug conjugates and methods of use
RU2018120696A (en) ANTI-CD22 CONJUGATES ANTIBODY-MAYTANSIN AND WAYS OF THEIR APPLICATION
MX2022006519A (en) Polyethylene glycol conjugate medicament, preparation method therfor and use thereof.
WO2018160178A8 (en) Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
WO2017165822A8 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
ZA202308282B (en) Toxin molecule suitable for antibody-drug conjugate
KR20200126334A (en) Adjuvant for cancer immunotherapy
PH12020500417A1 (en) Anti-efgr antibody drug conjugates (adc) and uses thereof
WO2019131722A1 (en) Conjugate of wt1-derived peptide and composition including same